Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 3;33(4):607-618.
doi: 10.1136/ijgc-2022-003719.

Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?

Cristiana Marques  1 , Filipa Ferreira da Silva  2 , Isabel Sousa  3   4 , Mónica Nave  5   6
Affiliations
Review

Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?

Cristiana Marques et al. Int J Gynecol Cancer. .

Abstract

Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.

Keywords: gynecology; medical oncology; ovarian cancer; ovarian neoplasms; ovary.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CM received honoraria from GSK, Astra Zeneca, MSD, and Pfizer. IS received honoraria from Astra Zeneca, GSK, MSD, and Pfizer. FFdS received honoraria from Astra Zeneca, GSK, and MSD. MN received honoraria from Astra Zeneca, GSK, MSD, and Pfizer.

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Torre LA, Trabert B, DeSantis CE, et al. . Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284–96. 10.3322/caac.21456 - DOI - PMC - PubMed
    1. Burger RA, Brady MF, Bookman MA, et al. . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473–83. 10.1056/NEJMoa1104390 - DOI - PubMed
    1. Hanker LC, Loibl S, Burchardi N, et al. . The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012;23:2605–12. 10.1093/annonc/mds203 - DOI - PubMed
    1. Wagner U, Marth C, Largillier R, et al. . Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012;107:588–91. 10.1038/bjc.2012.307 - DOI - PMC - PubMed

Publication types

Substances